Cantor Fitzgerald Cuts Price Target on Celldex (CLDX) to $31 Following Rintega Filing Delay
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Roth Capital Trims PT on Celldex (CLDX) to $39 Following Q2 Results; Would be Buyers on Weakness
August 11, 2015 8:11 AM EDTRoth Capital trims its price target on Celldex Therapeutics (Nasdaq: CLDX) from $43 down to $39 following Q2 results issued after markets closed Monday.
Analyst Joseph Pantginis commented, The key point to the 2Q15 results call, which we believe will drive perception for the... More
Brean Capital Cuts Price Target on Celldex (CLDX) Following Talks with FDA
August 11, 2015 7:07 AM EDTBrean Capital maintained a Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $31.00 (from $35.00), following company talks with the FDA. CLDX has received enough feedback to conclude that it will not file Rintega for Accelerated Approval in recurrent GBM.
Analyst... More
Cowen Cuts Price Target on Celldex (CLDX) Following 2Q and Clinical Update
August 11, 2015 6:58 AM EDTCowen maintained an Outperform rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $28.00 (from $34.00), following 2Q earnings and clinical update. CLDX has decided not to file for acceleration of Rintega. Analyst Boris Peaker is disappointed by the rindo filing... More
Celldex (CLDX) Reports Q2 Loss of $0.33
August 10, 2015 4:51 PM EDTCelldex (NASDAQ: CLDX) reported Q2 EPS of ($0.33), versus ($0.32) reported last year. Revenue for the quarter came in at $2.2 million, versus $592 thousand reported last year.
For earnings history and earnings-related data on Celldex (CLDX) click here.
... More